Waldenstrom Macroglobulinemia Clinical Trials

A listing of Waldenstrom Macroglobulinemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003)

lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenstrm's macroglobulinemia (WM).

measurable disease
mantle cell lymphoma
kinase inhibitor
leukemia
hepatitis b surface antigen
  • 0 views
  • 16 Jun, 2021
  • 9 locations
Bendamustine Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC

  • 0 views
  • 14 May, 2021
  • 2 locations
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and

  • 8 views
  • 08 Nov, 2020
  • 1 location
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenstrm's macroglobulinemia

measurable disease
bortezomib
lenalidomide
rituximab
dexamethasone
  • 0 views
  • 26 Jan, 2021
  • 1 location
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will

fludarabine
neutrophil count
lymphoma
cyclophosphamide
dexamethasone
  • 0 views
  • 24 Jan, 2021
  • 1 location
Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia

This phase II trial studies the side effects of ibrutinib citrate when given with ixazomib, and determines how well they work in treating participants with Waldenstrom macroglobulinemia that has

  • 7 views
  • 25 Mar, 2021
  • 1 location
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

  • 0 views
  • 24 Jan, 2021
  • 16 locations
Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia

), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with

positron emission tomography
progressive disease
proteasome inhibitor
plasmacytoma
lymphoid leukemia
  • 646 views
  • 04 Feb, 2021
  • 10 locations
Daratumumab Plus Ibrutinib in Patients With Waldenstr m's Macroglobulinemia

This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrm's macroglobulinemia (WM). The study will evaluate this combination in two

measurable disease
neutrophil count
igm level
cytopenia
human chorionic gonadotropin
  • 1 views
  • 27 Jan, 2021
  • 1 location
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenstr m Macroglobulinemia OBI-1

relapsed/refractory Waldenstrm Macroglobulinemia (R/R MW).

neutrophil count
monoclonal antibody therapy
monoclonal antibodies
platelet count
obinutuzumab
  • 13 views
  • 22 Jan, 2021
  • 2 locations